Pieris Pharmaceuticals (PIRS) Presents at ESMO Virtual Congress - Slideshow

1 A Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-positive Malignancies Authors: Sarina Piha-Paul1, Johanna Bendell2, Anthony Tolcher3, Sara Hurvitz4, Anuradha Krishnamurthy5, Anthony El-Khoueiry6, Amita Patnaik7, Rachna Shroff8, Anne Noonan9, Paula Pohlmann10, Noah Hahn11, Marc Matrana12, Markus Zettl13, Kayti Aviano13, Lynn Mar13, Patrick Jolicoeur13, Shane Olwill13, Ingmar Bruns13, Geoffrey Ku14 1The University of Texas MD Anderson Cancer Center, Texas, ...